Yiteng pharmaceutical and Ablynx reached a cooperation agreement on the nanotherapy antibody alx-0141 for osteoporosis

On October 14, 2013, Yiteng pharmaceutical, a fast-growing professional pharmaceutical company in China, announced a cooperation with Ablynx pharmaceutical Yiteng pharmaceutical was authorized by Ablynx pharmaceutical to develop, register and commercialize its nano antibody product alx-0141 in mainland China, Hong Kong, Macao and Taiwan, which is mainly used for indications such as osteoporosis and cancer bone metastasis Ablynx Pharmaceutical Co., Ltd is an internationally renowned nano antibody R & D pharmaceutical company Yiteng pharmaceutical and Ablynx pharmaceutical will greatly meet the growing demand of China's osteoporosis prevention and control market Mr Ni Xin, chairman and CEO of Yiteng pharmaceutical, said that he was very pleased to accept the entrustment of Ablynx pharmaceutical to develop and commercialize anti RANKL nano antibody products in Greater China "We will work hand in hand with Ablynx to deliver innovative drugs and health to a wide range of Chinese patients," he said Regarding the cooperation with Yiteng pharmaceutical, Mr Edwin Moses, chairman of Ablynx pharmaceutical, praised that "Yiteng pharmaceutical has the best conditions to further develop and commercialize alx0141 in the Greater China region, and the product has achieved rapid growth in the field of bone related diseases We are very looking forward to working together with Yiteng pharmaceutical, and will give Yiteng the greatest support in the follow-up development process of products and commercialization! " At present, the number of people suffering from osteoporosis is increasing year by year With the increasing trend of population aging, the improvement of people's living standards and the strengthening of bone health awareness, the osteoporosis prevention and treatment market is experiencing an unprecedented explosive growth According to the latest research report released by transparency market, the compound growth rate of China's osteoporosis drug market from 2010 to 2015 will reach 13.5% to US $2.5 billion It is reported that the nano antibody drugs of Ablynx pharmaceutical have significant safety and many characteristics with good efficacy for the detection of biomarkers, which make it have great potential in related fields Alx-0141 is a new product for bone diseases According to the results of a clinical test for healthy menopausal women, the single administration of alx0141 has a strong and long-term inhibitory effect on bone resorption biomarkers The patient was well tolerated without serious side effects or toxic reactions due to dose limitation.